Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marla C Dubinsky

Showing results (61-70 of 286) with videos related to

Pageof 29
Sort By:
Inflammatory Bowel Diseases|March 16, 2017
Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician VisitsDavid T Rubin, Marla C Dubinsky, Steve Martino, et al.
The AAPS Journal|October 15, 2016
Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD PatientsMarla C Dubinsky, Becky L Phan, Namita Singh, et al.
Digestive Diseases and Sciences|July 22, 2020
Identifying Patient Priorities for Preconception and Pregnancy Counseling in IBDAiya Aboubakr, Alexa Rae Riggs, Darwin Jimenez, et al.
Journal of Crohn'S & Colitis|May 2, 2025
Early intestinal ultrasound response to biologic and small molecule therapy is accurate to predict treat-to-target endoscopic outcomes in children with ulcerative colitis: results from the prospective super sonic-UC studyMichael Todd Dolinger, Illya Aronskyy, Elizabeth A Spencer, et al.
Inflammatory Bowel Diseases|September 18, 2021
Impact of Thiopurine Exposure on Immunogenicity to Infliximab Is Negligible in the Setting of Elevated Infliximab ConcentrationsRyan C Ungaro, Jean-Frederic Colombel, Marla C Dubinsky, et al.
Trends in Pharmacological Sciences|December 4, 2024
Model-informed precision dosing in inflammatory bowel diseasesArno R Bourgonje, Marla C Dubinsky, Ron J Keizer, et al.
The American Journal of Gastroenterology|January 9, 2023
Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn's Disease: A Post Hoc Analysis of the REACH TrialAdam S Cheifetz, Niels Vande Casteele, Zhongya Wang, et al.
Archives of Pathology & Laboratory Medicine|December 25, 2003
Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapySunita Shastri, Marla C Dubinsky, F Fred Poordad, et al.
The American Journal of Gastroenterology|August 29, 2024
Endoscopic Response Reduces the Risk of Subsequent Pouchitis in Patients With Crohn's Disease-Like Pouch InflammationMaia Kayal, Hannah Posner, Darwin Jimenez, et al.
Inflammatory Bowel Diseases|July 23, 2020
High Levels of Psychological Resilience Associated With Less Disease Activity, Better Quality of Life, and Fewer Surgeries in Inflammatory Bowel DiseasePriya Sehgal, Ryan C Ungaro, Carol Foltz, et al.
Pageof 29

Showing results (61-70 of 286) with videos related to

Sort By:
Pageof 29
Inflammatory Bowel Diseases|March 16, 2017
Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician VisitsDavid T Rubin, Marla C Dubinsky, Steve Martino, et al.
The AAPS Journal|October 15, 2016
Pharmacokinetic Dashboard-Recommended Dosing Is Different than Standard of Care Dosing in Infliximab-Treated Pediatric IBD PatientsMarla C Dubinsky, Becky L Phan, Namita Singh, et al.
Digestive Diseases and Sciences|July 22, 2020
Identifying Patient Priorities for Preconception and Pregnancy Counseling in IBDAiya Aboubakr, Alexa Rae Riggs, Darwin Jimenez, et al.
Journal of Crohn'S & Colitis|May 2, 2025
Early intestinal ultrasound response to biologic and small molecule therapy is accurate to predict treat-to-target endoscopic outcomes in children with ulcerative colitis: results from the prospective super sonic-UC studyMichael Todd Dolinger, Illya Aronskyy, Elizabeth A Spencer, et al.
Inflammatory Bowel Diseases|September 18, 2021
Impact of Thiopurine Exposure on Immunogenicity to Infliximab Is Negligible in the Setting of Elevated Infliximab ConcentrationsRyan C Ungaro, Jean-Frederic Colombel, Marla C Dubinsky, et al.
Trends in Pharmacological Sciences|December 4, 2024
Model-informed precision dosing in inflammatory bowel diseasesArno R Bourgonje, Marla C Dubinsky, Ron J Keizer, et al.
The American Journal of Gastroenterology|January 9, 2023
Higher Postinduction Infliximab Concentrations Are Associated With Favorable Clinical Outcomes in Pediatric Crohn's Disease: A Post Hoc Analysis of the REACH TrialAdam S Cheifetz, Niels Vande Casteele, Zhongya Wang, et al.
Archives of Pathology & Laboratory Medicine|December 25, 2003
Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapySunita Shastri, Marla C Dubinsky, F Fred Poordad, et al.
The American Journal of Gastroenterology|August 29, 2024
Endoscopic Response Reduces the Risk of Subsequent Pouchitis in Patients With Crohn's Disease-Like Pouch InflammationMaia Kayal, Hannah Posner, Darwin Jimenez, et al.
Inflammatory Bowel Diseases|July 23, 2020
High Levels of Psychological Resilience Associated With Less Disease Activity, Better Quality of Life, and Fewer Surgeries in Inflammatory Bowel DiseasePriya Sehgal, Ryan C Ungaro, Carol Foltz, et al.
Pageof 29